<SUBMISSION>
<ACCESSION-NUMBER>0000950153-06-003039
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>2
<PERIOD>20061213
<ITEMS>8.01
<ITEMS>9.01
<FILING-DATE>20061220
<DATE-OF-FILING-DATE-CHANGE>20061220
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>TASER INTERNATIONAL INC
<CIK>0001069183
<ASSIGNED-SIC>3480
<IRS-NUMBER>860741227
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>001-16391
<FILM-NUMBER>061290352
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>7860 EAST MCLAIN DR.
<STREET2>SUITE 2
<CITY>SCOTTSDALE
<STATE>AZ
<ZIP>85260
<PHONE>4809052000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>7860 EAST MCLAIN DR.
<STREET2>SUITE 2
<CITY>SCOTTSDALE
<STATE>AZ
<ZIP>85260
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>p73276e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Washington, DC 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of<BR>
The Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported)</B></DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>December
13, 2006</B>

</DIV>
<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>TASER International, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>001-16391</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>86-0741227</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>17800 N. 85<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> St.<BR>
Scottsdale, Arizona 85255</B><BR>
(Address of principal executive offices, including zip code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(480)&nbsp;991-0797</B><BR>
(Registrant&#146;s telephone number, including area code)</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">(Former name or former address, if changed since last report)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">






<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">ITEM 8.01. OTHER EVENTS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">EXHIBIT INDEX</A></TD></TR>
<TR><TD colspan="9"><A HREF="p73276exv10w18.htm">EX-10.18</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "ITEM 8.01. OTHER EVENTS " -->
<DIV align="left"><A NAME="000"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 8.01. OTHER EVENTS.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TASER International, Inc. (the &#147;Company&#148;), certain of its former and current officers and
directors, and plaintiffs in certain shareholder derivative actions have executed a stipulation
dated December&nbsp;4, 2006 to settle the shareholder derivative actions. On December&nbsp;13, 2006, the
U.S. District Court for the District of Arizona, in the action titled <U>In re TASER International
Shareholder Derivative Litigation</U>, Case No.&nbsp;CV-05-123-PHX-SRB, entered an order preliminarily
approving the settlement. Pursuant to that order, the Company provides the &#147;Notice of Settlement of Shareholder
Derivative Action&#148; attached hereto as Exhibit&nbsp;10.18.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">
</DIV>

<!-- link1 "ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS" -->
<DIV align="left"><A NAME="001"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Exhibits.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="81%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Exhibit No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.18
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notice of Settlement of Shareholder Derivative Action</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">Dated: December 20, 2006&nbsp;</TD>
    <TD colspan="3" align="left">TASER International, Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ DANIEL BEHRENDT
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Daniel Behrendt&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "EXHIBIT INDEX" -->
<DIV align="left"><A NAME="003"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT INDEX
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="14%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="81%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="center" style="border-bottom: 1px solid #000000">Exhibit No.</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000">Description</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD align="center" valign="top"><DIV style="margin-left:0px; text-indent:-0px">10.18
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Notice of Settlement of Shareholder Derivative Action</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>2
<FILENAME>p73276exv10w18.htm
<DESCRIPTION>EX-10.18
<TEXT>
<HTML>
<HEAD>
<TITLE>exv10w18</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>EXHIBIT 10.18</B></U>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">UNITED STATES DISTRICT COURT

</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt">DISTRICT OF ARIZONA

</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="37%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="57%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="left" valign="top">IN RE TASER INTERNATIONAL
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Lead Case No.&nbsp;05-0123-PHX-SRB</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">SHAREHOLDER DERIVATIVE</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="left" valign="top">LITIGATION</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">This Document Relates To:
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>NOTICE OF SETTLEMENT OF</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>SHAREHOLDER DERIVATIVE</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">ALL ACTIONS.
</TD>
    <TD>&nbsp;</TD>

<TD align="left" valign="top"><DIV style="margin-left:28%"><B>ACTION</B></DIV></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD align="center" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>NOTICE OF SETTLEMENT HEARING</B></U>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><b>TO:</b></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>ALL RECORD AND/OR BENEFICIAL OWNERS OF TASER INTERNATIONAL, INC. COMMON STOCK AS OF DECEMBER
4, 2006 (&#147;CURRENT TASER STOCKHOLDERS&#148;):</B></TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. IF YOU ARE A CURRENT TASER
STOCKHOLDER, THE SETTLEMENT OF THE ACTIONS DESCRIBED HEREIN COULD AFFECT YOUR RIGHTS. THESE
ACTIONS ARE NOT &#147;SECURITIES CLASS ACTIONS&#148; AND THERE IS NO SETTLEMENT FUND ON WHICH TO MAKE
A CLAIM.</B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS NOTICE IS PROVIDED pursuant to an Order of the United States District Court for the
District of Arizona (the &#147;Court&#148;) in the above-captioned shareholder derivative action.
Representative Plaintiffs brought the above-captioned action and two related state court actions
 </DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(collectively, the &#147;Actions&#148;) derivatively on behalf of TASER International, Inc. (&#147;TASER&#148; or
the &#147;Company&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Settling Parties to the Actions have entered into a Stipulation of Settlement dated
December&nbsp;4, 2006 (the &#147;Stipulation&#148;) which provides for, among other things, the settlement and
dismissal of the Actions (the &#147;Settlement&#148;). Thus, you are hereby notified, pursuant to Federal
Rule of Civil Procedure 23.1 and an Order of the Court, that a final settlement hearing (the
&#147;Settlement Hearing&#148;) will be held in the Actions on
March&nbsp;12, 2007 at 4:00&nbsp;p.m. at the United
States District Court for District of Arizona, Sandra Day O&#146;Connor United States Courthouse, which
is located at 401 West Washington Street, Phoenix, Arizona 85003-2118, in the Courtroom of the
Honorable Susan R. Bolton to, among other things: (i)&nbsp;determine the fairness, reasonableness, and
adequacy of the terms and conditions of the Settlement and whether the Court should finally approve
the Settlement and enter an Order and Final Judgment thereon; and (ii)&nbsp;rule upon the agreed-to fee
award for Federal Plaintiffs&#146; Lead Counsel in the Actions. Even though you are receiving this
Notice, the Court has not expressed any opinion as to the merits of any claim or defense that has
been or may be asserted in the Actions.
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%"><B>THE FOLLOWING RECITATION DOES NOT CONSTITUTE FINDINGS OF THE COURT. IT IS BASED ON
THE STATEMENTS OF THE SETTLING PARTIES AND SHOULD NOT BE UNDERSTOOD AS AN EXPRESSION
OF ANY OPINION OF THE COURT AS TO THE MERITS OF ANY OF THE CLAIMS OR DEFENSES RAISED
BY ANY OF THE SETTLING PARTIES.</B>
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>I.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>BACKGROUND</B></U></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On January&nbsp;11, 2005, Representative Plaintiffs in the Federal Action instituted litigation
on behalf of TASER against the Individual Defendants in the United States District Court for the
District of Arizona.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On February&nbsp;9, 2005, the Court in this &#147;Federal Action&#148; consolidated several derivative
actions as <I>In re TASER International Shareholder Derivative Litigation</I>, Case No.&nbsp;05-123-PHX-SRB
and appointed the Federal Plaintiffs&#146; Lead Counsel.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On May&nbsp;13, 2005, after their investigation, plaintiffs in the Federal Action filed their
Federal Complaint alleging on behalf of TASER claims against the Individual Defendants for breach
of fiduciary duty, abuse of control, gross mismanagement, waste of corporate assets and unjust
enrichment based on allegations that the Individual Defendants, among other things, with knowing
or extreme recklessness issued, or caused TASER to issue, a series of improper and misleading
statements regarding: (a)&nbsp;the Company&#146;s then-current operating condition and its future
prospects; and (b)&nbsp;the safety record of the Company&#146;s weapons; that the Individual Defendants&#146;
acts and failures to act had the effect of creating unwarranted market optimism, which in turn
caused the price of the Company&#146;s common stock to be artificially inflated throughout the
Relevant Period; that certain of TASER&#146;s officers and directors took advantage of the Company&#146;s
artificially inflated stock price by selling over 1.7&nbsp;million shares of their personally-held
stock for proceeds exceeding $88&nbsp;million; and that the foregoing conduct caused TASER to suffer
damages.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;19, 2005, TASER and the Individual Defendants moved to dismiss the Federal
Complaint, which was then fully briefed by all parties in the Federal Action, and on March&nbsp;17,
2006, the Court denied the motions of both TASER and the Individual Defendants.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following events occurred in the Arizona State Court Action: (i)&nbsp;on January&nbsp;12, 2005,
plaintiffs initiated litigation in the Arizona Superior Court for Maricopa County on behalf of
TASER against certain of the Individual Defendants; (ii)&nbsp;on May&nbsp;3, 2005, the Court entered an
order consolidating related actions as <I>In re TASER International, Inc. Shareholder Derivative
Litigation</I>, Case No.&nbsp;CV 2005-684; (iii)&nbsp;on April&nbsp;5, 2005, plaintiffs filed a Verified
Consolidated Derivative Complaint on behalf of TASER against certain of the Individual Defendants
claiming breach of fiduciary duty and unjust enrichment based on allegations substantially
similar to the allegations of the Federal Complaint; and (iv)&nbsp;on July&nbsp;25, 2005, the Court issued
an order in part staying further litigation of the Arizona State Court Action pending resolution
of the Federal Action.
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following events occurred in the Delaware State Court Action: (i)&nbsp;on January&nbsp;13, 2005,
plaintiffs initiated litigation in the Court of Chancery of the State of Delaware for New Castle
County, by filing a Derivative Complaint captioned <I>Rosenberg v. Smith, et al.</I>, Case No.&nbsp;1000-N,
on behalf of TASER against certain of the Individual Defendants claiming breach of fiduciary duty
based on substantially similar allegations as alleged in the Federal Complaint, and (ii)&nbsp;on
September&nbsp;13, 2005, the Court issued an order staying further litigation of the Delaware State
Court Action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Individual Defendants have denied and continued to deny all the claims and allegations
against them in the Actions, TASER has asserted and continues to assert that the Representative
Plaintiffs in the Actions do not have standing to bring such claims against the Individual
Defendants on behalf of TASER and that Representative Plaintiffs&#146; failure to make a
pre-litigation demand on TASER&#146;s Board of Directors is not excused.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In and around April&nbsp;2006, the parties in the Federal Action began private settlement
discussions, resulting in a mediation session on July&nbsp;25, 2006 before the Hon. Layn R. Phillips
(ret.), with whose assistance the parties were able to reach the terms of settlement set forth in
the Stipulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August&nbsp;2006, Representative Plaintiffs in the State Court Actions, through their counsel,
confirmed to Federal Plaintiffs&#146; Lead Counsel and counsel for Defendants that the Representative
Plaintiffs in the State Court Actions intend to dismiss their respective actions as part of and
in conjunction with the settlement and dismissal of the Federal Action.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>II.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B><u>THE SETTLING PARTIES&#146; POSITIONS REGARDING THE DESIRABILITY OF THE SETTLEMENT</U></B></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Individual Defendants expressly have denied and continue to deny each and all of the
allegations and claims alleged in the Actions. The Individual Defendants expressly have denied and
continue to deny all charges of wrongdoing or liability against them, arising out of any of the
conduct, statements, acts or omissions alleged, or that could have been alleged in the
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">Actions. The Individual Defendants also have denied and continue to deny, <I>inter alia</I>, the
allegations that Representative Plaintiffs or TASER or its stockholders were harmed by the conduct
alleged in the Actions. The Individual Defendants further have denied and continue to deny that
they are liable to TASER for any claims, causes of action, costs, expenses, attorneys&#146; fees or
damages of any kind. The Individual Defendants have further asserted that, at all relevant times,
they acted in good faith and in a manner they reasonably believed to be in the best interests of
TASER and TASER&#146;s stockholders.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TASER has denied and continues to deny that Representative Plaintiffs have standing to assert
the claims in their respective Actions against the Individual Defendants. TASER has asserted and
continues to assert that Representative Plaintiffs&#146; failure to make a pre-litigation demand on
TASER&#146;s Board is not excused.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nonetheless, TASER and Individual Defendants have concluded that further litigation of the
Actions would be protracted and expensive, and that it is desirable that the Actions be fully and
finally settled in the manner and upon the terms and conditions set forth in this Stipulation.
TASER and Individual Defendants also have taken into account the uncertainty and risks inherent in
any litigation and, therefore, determined that it is desirable and beneficial that the Actions be
settled in the manner and upon the terms and conditions set forth in the Stipulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal Plaintiffs&#146; Lead Counsel asserts that they have conducted extensive discovery and
investigation during the development and prosecution of the Federal Action. This discovery and
investigation has included, <I>inter alia</I>; (i)&nbsp;inspecting, reviewing and analyzing thousands of pages
of documents produced by, or otherwise relating to, TASER; (ii)&nbsp;consulting with corporate
governance experts; (iii)&nbsp;participating in numerous face-to-face and telephonic meetings with
TASER&#146;S counsel, and some of the Individual Defendants identified herein; (vi)&nbsp;participating in
formal mediation with a highly experienced mediator retained to assist resolving the Federal
Action; and (v)&nbsp;researching the applicable law with respect to the claims asserted in the Federal
Action and the potential defenses thereto.
 </DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representative Plaintiffs and All Plaintiffs&#146; Counsel believe that the claims asserted in the
Actions have merit. They recognize and acknowledge, however, the extraordinary expense and length
of continued proceedings necessary to prosecute the Actions against the Individual Defendants on
TASER&#146;S behalf through trial and, potentially, through appeals. They also recognize the inherent
risks of an uncertain outcome, especially in complex litigation such as the Actions, as well as
the difficulties and delays of such litigation. Taking these risks, uncertainties and expenses
into consideration, Representative Plaintiffs and All Plaintiffs&#146; Counsel believe that the
Settlement set forth in the Stipulation confers substantial benefits upon TASER. Based on their
evaluation, Representative Plaintiffs and All Plaintiffs&#146; Counsel have determined that the
Settlement set forth in the Stipulation is in the best interests of Representative Plaintiffs,
TASER and TASER&#146;s stockholders.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>III.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>THE TERMS OF THE PROPOSED SETTLEMENT</B></U></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the filing, prosecution and settlement negotiations leading to the
Stipulation, Defendants and their insurance carrier have resolved claims under the effective
insurance policy so that the insurance carrier has agreed to make available to TASER $4.8&nbsp;million
of its $5.0&nbsp;million insurance policy for defense and/or settlement of pending securities claims,
to release any right to seek repayment of the $4.8&nbsp;million, and to remit to TASER $4.8&nbsp;million
less certain defense costs paid to date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the filing, prosecution and settlement negotiations leading to the
Stipulation, the Company will adopt the following corporate changes or provisions: (1)
appointment of a lead outside director to be chosen from among the recently appointed independent
directors whose duties will include among other responsibilities chairing executive sessions of
the Board, serving as the principal liaison between the non-employee directors and members of
senior management, representing the Board in meetings with investors, and working with the
Chairperson to finalize information flow to the Board, meeting agendas and meeting schedules; (2)
review and as appropriate revise the Company&#146;s formal

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">insider trading policy; and (3)&nbsp;has contracted its internal audit function to an independent
third party until the first to occur of (i)&nbsp;such time that TASER no longer is required to comply
with the provisions of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, (ii)&nbsp;TASER employs an
internal audit manager, or (iii)&nbsp;there is a &#147;change of control&#148; of TASER defined as the closing
of a merger, reorganization, consolidation or other transaction or related series of transactions
as a result of which the stockholders of TASER prior to such transaction do not hold at least a
majority of the voting stock of the acquiring or successor corporation or its parent company.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result, in part, of the filing, prosecution and settlement negotiations leading to this
Stipulation, the Company has added two (2)&nbsp;new independent directors to the Board.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Settling Parties believe that the foregoing corporate changes or provisions have
benefited and will continue to materially benefit TASER and Current TASER Stockholders.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>IV.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>SETTLEMENT HEARING AND APPROVAL</B></U></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>On
March&nbsp;12, 2007 at 4:00&nbsp;p.m. the Court will hold a Settlement Hearing at the United States
District Court for District of Arizona, Sandra Day O&#146;Connor United States Courthouse, before the
Hon. Susan Bolton to consider the approval of the Settlement on the terms set forth above.</I></B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>PLEASE TAKE NOTE: YOUR RIGHTS MAY BE AFFECTED </B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Court approves the Settlement and enters the Final Judgment and Order of Dismissal with
Prejudice, upon the Effective Date, Representative Plaintiffs, and All Plaintiffs&#146; Counsel on their
own behalf and derivative on behalf of TASER, and Current TASER Stockholders (in their capacity as
stockholders only) shall fully, finally and forever relinquish and discharge all Released Claims
(including &#147;Unknown Claims&#148;) against each an all of the Released Persons. Each of the
Representative Plaintiffs, All Plaintiffs&#146; Counsel, and the Current TASER Stockholders may
hereafter discover facts in addition to or different from those which he or she now knows or
believes to be true with respect to the subject matter of the Released Claims, but they stipulate
and agree that the Representative Plaintiffs, All Plaintiffs&#146; Counsel,

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">and each Current TASER Stockholder shall be deemed to, upon the Effective Date, fully,
finally, and forever settle and release any and all Released Claims, which now exist, or heretofore
have existed upon any theory of law or equity, including, but not limited to, conduct which is
negligent, intentional, with or without malice, or a breach of any duty, law or rule, without
regard to the subsequent discovery or existence of such different or additional facts.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>V.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>ATTORNEYS&#146; FEES AND REIMBURSEMENT OF EXPENSES</B></U></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TASER, on behalf of all Defendants, has agreed, upon approval by the Court, that for Federal
Plaintiffs&#146; Lead Counsel&#146;s efforts in filing, prosecuting and settling the Action, TASER shall pay
to Federal Plaintiffs&#146; Lead Counsel attorneys&#146; fees and reimbursement of expenses in the amount of
$1,750,000.00 (the &#147;Fee Award&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Fee Award shall be paid to Federal Plaintiffs&#146; Lead Counsel in the form of TASER common
stock no later than ten (10)&nbsp;business days after the Effective Date (the &#147;Payment Date&#148;). Payment
shall be made in a certain number of TASER common shares equal to the Fee Award (&#147;the Base
Number&#148;). The Base Number shall be calculated based on the average of the closing prices of TASER
common stock during the period of thirty (30)&nbsp;calendar days after the date the Court in the Federal
Action enters Judgment (the &#147;Base Number Price&#148;). The Fee Award shall be calculated as the number
of TASER common shares equal to $1,750,000.00 divided by the Base Number Price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Fee Award will also be subject to a collar provision for the benefit of Federal
Plaintiffs&#146; Lead Counsel or TASER. The &#147;Collar Price&#148; shall be the average of the closing prices
of TASER common stock during the period of thirty (30)&nbsp;calendar days preceding the five (5)
business days before the Payment Date. The collar provision provided in this paragraph becomes
effective only if either 1) the Base Number Price is greater than one hundred ten percent (110%) of
the Collar Price, or 2) the Base Number Price is less than ninety percent (90%) of the Collar
Price. If the collar provision does not become effective, then the Fee Award is determined
pursuant to the preceding paragraph. If the collar provision becomes effective,

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">then the Fee Award shall be the number of TASER common shares equal to $1,750,000.00 divided
by the Collar Price.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Fee Award is also subject to other modifications in the event that there is a change of
control of TASER, as set forth in Paragraph&nbsp;9.6 of the Stipulation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Fee Award includes fees and expenses incurred by All Plaintiffs&#146; Counsel in connection
with the prosecution and settlement of the Actions. To date, All Plaintiffs&#146; Counsel have not
received any fees, nor have they been reimbursed for their out of pocket expenses. The Fee Award
would compensate All Plaintiffs&#146; Counsel for the results achieved in the Actions, and risks of
undertaking the prosecution of the Actions on a contingent basis.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any stock distributed as part of the Settlement shall be issued pursuant to Section&nbsp;3(a)(10)
of the Securities Act of 1933, and shall not be constituted &#147;restricted securities.&#148; In the event
that the stock cannot be issued pursuant to Section&nbsp;3(a)(10), TASER shall take such steps as are
necessary to permit such issuance or, in lieu thereof, shall file a registration statement covering
the issuance of such stock or seek a &#147;no action&#148; letter from the Securities and Exchange Commission
covering such issuance. Furthermore, in the event that such stock cannot be issued pursuant to
Section&nbsp;3(a)(10) and TASER files a registration statement with respect to the shares as
contemplated by the preceding sentence, TASER agrees that during the initial period that any such
stock is not otherwise freely tradable and transferable under Rule 144(k) or otherwise, TASER will,
at its sole cost, keep a registration statement relating to such TASER common stock effective under
the Securities Act of 1933.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Defendants and their respective Related Parties shall have no responsibility for, and no
liability whatsoever with respect to, the fee allocation among All Plaintiffs&#146; Counsel, and any
other Person who may assert some claim thereto, of any portion of the Fees and Expenses.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>VI.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>YOUR RIGHT TO BE HEARD AT THE HEARING</B></U></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any Current TASER Stockholder may (but is not required to) appear and show cause, if he, she
or it has any reason why the Settlement of the Actions embodied in the Stipulation should

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">not be approved as fair, reasonable and adequate, or why a judgment should or should not be entered
thereon, or why fees inclusive of expenses should not be awarded as agreed upon by the Settling
Parties; provided however, that no Current TASER Stockholder or any other Person, shall be heard or
entitled to contest the approval of the Settlement, or, if approved, the Judgment to be entered
thereon, unless on or before ten business (10)&nbsp;days prior to the Settlement Hearing that Person has
caused to be filed written objections, stating all supporting bases and reasons, with:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 23%; margin-top: 6pt"><B>CLERK OF THE COURT</B><BR>
United States District Court for the District of Arizona<BR>
Phoenix Division<BR>
Sandra Day O&#146;Connor U.S. Courthouse,<BR>
401 West Washington Street, Suite&nbsp;130, SPC1<BR>
Phoenix, Arizona 85003-2118
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and has served copies of all such papers at the same time upon the following by first-class mail:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="49%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert B. Weiser, Esq.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Keith E. Eggleton, Esq.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">The Weiser Law Firm, P.C.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Wilson Sonsini Goodrich &#038; Rosati, LLP</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">121 N. Wayne Ave., Suite&nbsp;100
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">650 Page Mill Road</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Wayne, PA 19087
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Palo Alto, CA 94304-1050</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><B>Federal Plaintiffs&#146; Lead Counsel</B>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>Individual Defendants&#146; Counsel</B></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Holly L. Gibeaut</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">TASER International, Inc.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">17800 N. 85th St.</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Scottsdale, AZ 85255-9603</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><B>TASER&#146;s Counsel</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attendance at the Settlement Hearing is not necessary in order for the objection to be
considered by the Court; however, Persons wishing to be heard orally in opposition to the approval
of the Settlement are required to indicate in their written objection their intention to appear at
the hearing. Thus, every written objection filed with the Court and mailed to the attorneys listed
above must contain: (1)&nbsp;the name, address and telephone number of the Person objecting to the
Settlement; (2)&nbsp;the number of shares of TASER common stock said Person owns; (3)&nbsp;the date(s) of
purchase of such shares, and a statement as to whether the Person will own such shares as of the
date of the Settlement Hearing; (4)&nbsp;a detailed statement of the basis for the Person&#146;s objections
to or comments upon the Settlement, All Plaintiffs&#146; Counsel&#146;s request

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">for approval of the Fee Award, or any other matter before the Court; (5)&nbsp;any supporting
papers, including all documents and writings that the Person desires the Court to consider; (6)&nbsp;a
representation as to whether the Person intends to appear at the Settlement Hearing; (7)&nbsp;a
representation as to whether the Person plans on calling any witness&#091;es&#093; at the Settlement Hearing;
and (8)&nbsp;the identities of any witnesses the Person plans to call at the Settlement Hearing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B><I>Any Current TASER Stockholder who does not make his, her or its objection in the manner
provided in the preceding paragraph of this Order shall be deemed to have waived such objection and
shall forever be foreclosed from making any objections to the fairness, adequacy, or reasonableness
of the Settlement, or the Fee Award.</I></B>
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>VII.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>SCOPE OF THIS NOTICE</B></U></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The foregoing descriptions of the Actions, the Settlement Hearing, the proceedings to be held,
the activities leading to the Settlement, the terms of the Settlement, the conditions of
Settlement, and other matters described herein do not purport to be all inclusive. Accordingly,
you are referred to the Stipulation and other pleadings filed with the Clerk of the Court, which
may be examined during regular business hours at the offices of the Clerk of the Court at United
States District Court for the District of Arizona, Phoenix Division, Sandra Day O&#146;Connor U.S.
Courthouse, 401 West Washington Street, Suite&nbsp;130, SPC1, Phoenix, Arizona 85003-2118.
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><B>VIII.</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><U><B>QUESTIONS REGARDING THE PROPOSED SETTLEMENT</B></U></TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; line-height:20pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you have questions regarding the Settlement, this Notice, or the history of the Actions,
<B><I>please do not call or write the Court or the Company. </I></B>Questions may be directed to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 23%; margin-top: 6pt">Robert B. Weiser, Esq.<BR>
The Weiser Law Firm, P.C.<BR>
121 N. Wayne Ave., Suite&nbsp;100<BR>
Wayne, PA 19087<BR>
(866)&nbsp;934-7372<BR>
<B>Federal Plaintiffs&#146; Lead Counsel</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
